ARCT Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at upcoming investor and scientific conferences virtually:

• TIDES: Oligonucleotide and Peptide Therapeutics scientific conference PresentationDate: Wednesday, September 9, 2020Time: On-line
• Baird Global Healthcare ConferencePresentationDate: Wednesday, September 9, 2020Time: 1:25 p.m. ET
• Citi 15th Annual BioPharma ConferencePanelDate: Thursday, September 10, 2020Time: 1:30 p.m. ET
• UBS COVID-19 Vaccine Symposium Fireside ChatDate: Friday, September 11, 2020Time: 3:50 p.m. ET
• H.C. Wainwright & Co. 22nd Annual Global Investment ConferencePresentationDate: Monday, September 14, 2020Time: 11:00 a.m. ET

The events above may be accessed on the Arcturus website in the Investors Relation section, under Events and Presentations for approximately 30 days following the events.

About Arcturus TherapeuticsFounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com

IR and Media ContactsArcturus TherapeuticsNeda Safarzadeh (858) 900-2682 IR@ArcturusRx.com

Kendall Investor RelationsCarlo Tanzi, Ph.D. (617) 914-0008  ctanzi@kendallir.com